11/01/2019 11:41:00

Holding(s) in Company

TwentyFour Income Fund - Holding(s) in Company

PR Newswire

TR-1: S

tandard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached

ii

:

TWENTYFOUR INCOME FUND LIMITED

1b. Please indicate if the issuer is a non-UK issuer   (please mark with an “X” if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an “X”)

An acquisition or disposal of voting rightsX
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)iii:

3. Details of person subject to the notification obligation

iv

NameSarasin & Partners LLP
City and country of registered office (if applicable)London, United Kingdom

4. Full name of shareholder(s) (if different from 3.)v

NameThe Bank of New York Mellon (Brussels (Pooled))

Citibank Europe PLC (Canary Wharf)

The Bank of New York Mellon (Brussels)

The Bank of New York Mellon (London)

The Northern Trust Company (London)

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached

vi

:

08/01/19

6. Date on which issuer notified (DD/MM/YYYY):

09/01/19

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments

(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached4.4068%0%4.4068%415,814,151
Position of previous notification (if

applicable)

9.17%9.17%

   

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

viii

A: Voting rights attached to shares

Class/type of

shares

ISIN code (if possible)

Number of voting rights

ix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GG00B90J5Z9518,324,0064.4068%

SUBTOTAL 8. A

18,324,0064.4068%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration

date

x

Exercise/

Conversion Period

xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration

date

x

Exercise/

Conversion Period

xi

Physical or cash

settlement

xii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

   

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an “X”)

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiiiX

Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Name

xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10.

In case of proxy voting, please identify:

Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information

xvi

   

Place of completion

Sarasin & Partners LLP

100 Juxon House,

St. Pauls Churchyard

London EC4M 8BU

Date of completion

09/01/19

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
13 Jun
PNDORA
Hvad er det for noget eklatant ævl.Hvis man sammenholder de store fondes indtog på det danske aktiem..
24
13 Jun
PNDORA
Jeg er meget imponeret over Jyske bank og i særdeleshed analytikkeren Janne Vincent Kjær. Kunne rest..
20
09 Jun
PNDORA
Ok ja. Og i Schweiz betaler hverken dem der arbejder eller firmaer noget særligt i skat og alligevel..
18
12 Jun
PNDORA
er i dag ude med en dødsdoms artikel omkring Pandora. Artiklen er skrevet af en velanset analytiker,..
17
12 Jun
NOVO-B
Novo Nordisk aktien er d.d. steget med 120 kr. siden d. 25. nov. 2016. Dvs. fra 226 til 346 kr. 💪 ..
17
10 Jun
VELO
https://clinicaltrials.gov/ct2/show/study/NCT03979365 Bliver også spændene, at se om Envarsus sna..
15
15 Jun
PNDORA
Udover den samme analyse blev offentligjort for snart 3 uger siden er det da glimrende at man igen, ..
14
13 Jun
PNDORA
Nå du mener som IKEA, KIA, Hyundai, Harald Nyborg, Jysk og alle de andre hvor ingen vil handle..;)Må..
13
13 Jun
 
Kildevand på flaske ligeledes. Forbyd det. Kildevand, der fragtes fra Frankrig og  Italien til Danma..
13
12 Jun
PNDORA
Uden at have noget kendskab til Per Hansen artiklen, så kan jeg med sikkerhed sige, at din kommentar..
13

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
2
REV DEADLINE: Rosen, a Highly Ranked Law Firm, Reminds Revlon, Inc. Investors of Important July 15th Deadline in Securities Class Action – REV
3
Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
4
FSIS Recall 069-2019 Foreign Matter Contamination: RUIZ FOODS PRODUCTS INC. RECALLS BACON BREAKFAST WRAP PRODUCTS DUE TO POSSIBLE FOREIGN MATTER CONTAMINATION
5
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 June 2019 04:33:56
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB1 - 2019-06-16 05:33:56 - 2019-06-16 04:33:56 - 1000 - Website: OKAY